delcath.com (DCTH) - Company Cash Volume

DCTH (Delcath) - company brandmark

Delcath Systems, Inc. (DCTH) is restructuring its operating model for commercial launch following the FDA verdict, although cash flows remain volatile due to the therapy implementation phase. Current cash levels reflect capital dynamics where the parameter has stabilized at 0.10. Strong patents protect the business from dumping, meaning success depends solely on clinical efficacy and recognition by the medical community.

Delcath - DCTH Company Cash Balance (period 07/04/2022 - 11/21/2026)

Summary analytical data breakdowns for Delcath Systems Inc (DCTH)

- current price and projected stock value:
Basic company analysis:Delcath DCTH
Product sample of Delcath Systems

The monopoly status of Delcath Systems, Inc. (DCTH) in melanoma treatment and its premium pricing ensure a flow of high-margin revenue. This indicator aggregates all cash and cash equivalents, determining the issuer's absolute liquidity and financial autonomy. Investors interpret this volume as a safety buffer for expansion or covering operating expenses. By analyzing the cash reserve dynamics, one can assess the efficiency of capital management during the commercial launch period.

Key competitors

Company Cash Volume ONC|HALO - Company Cash Reserve|Revolution Medicines - Company Cash on Hand|Company Cash Volume Ascentage Pharma AAPG|CGON - Company Cash Funds|Company Total Cash Volume URGN|BCAX: Company Cash Volume|PSNL - Company Liquid Assets|ERAS (Erasca Inc) - Company Cash Volume|Company Cash Reserve Y-mAbs Therapeutics Inc YMAB|Company Cash Volume AURA|CADL (Candel Therapeutics, Inc.) - Company Cash Balance|Company Cash Funds Accuray Inc ARAY|Company Liquid Assets SELLAS Life Sciences Group Inc. (SLS)|actuatetherapeutics.com - Company Cash Volume|Company Cash Reserve Citius Oncology|HURA: Company Cash Volume|Company Total Cash Volume TARA (Protara)|FATE (fatetherapeutics.com) - Company Cash Volume|Company Cash Reserve Aadi Bioscience WHWK|Company Cash Volume TCRX|CSBR - Company Cash Reserve|XBiotech - Company Cash on Hand|CEL-SCI Corporation (CVM) - Company Cash Reserve|OSTX - Company Cash Funds|Company Cash Reserve Radiopharm Theranostics Ltd|ARTV (artivabio.com) - Company Cash on Hand|ANL (Adlai Nortye Ltd) - Company Cash Funds|Company Cash on Hand VERU|Tempest Therapeutics (TPST) - Company Liquid Assets|Company Cash Volume XLO|Company Cash on Hand Renovaro RENB|Company Cash Volume MURA (Mural Oncology PLC)|KAPA - Company Cash on Hand|OnKure Therapeutics - Company Cash Volume|w2.cytomed.sg - Company Total Cash Amount|Curis Corp (CRIS) - Company Cash Funds|Company Cash Reserve Apollomics Corp (APLM)|Company Cash Funds Tharimmune|Company Cash Volume advanbiomed.com|Company Cash Funds Genprex, Inc (GNPX)|Company Liquid Assets Calidi Biotherapeutics, Inc.|Company Cash Volume SBFM (Sunshine Biopharma Inc.)|XBIO - Company Cash on Hand|SLRX: Company Cash on Hand|Company Cash Balance PPBT (Purple Biotech Ltd.)|AONC: Company Cash Volume|Company Cash Reserve BeOne Medicines (BGNE)|Company Cash Funds Checkpoint Therapeutics, Inc.|Company Cash on Hand Elevation Oncology (ELEV)|Company Cash Funds iCAD Corp (ICAD)|Company Cash on Hand Ikena IKNA|Company Cash Volume NTBL (notablelabs.com)|VIRX - Company Cash on Hand|MOR: Company Cash on Hand|NAYA - Company Cash Volume|Ascentage Pharma (AAPGV) - Company Cash Funds